This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed Alunbrig click here.

What is ALUNBRIG  (brigatinib)?

Brigatinib: A potent ALK inhibitor1

Brigatinib is a small molecule specifically designed to target ALK rearrangements in NSCLC1,2

  • Discovered and developed by Ariad, subsequently acquired by Takeda

Key structural features such as dimethylphosphine oxide contribute to its potency and selectivity2

  • Selectively inhibits ALK (IC50=0.6 nM) and ROS1 (IC50=1.9 nM)1*

Brigatinib binds to the ATP-binding site of ALK1,2

  • Inhibits 17 different ALK mutants at clinically achievable concentrations1*

*Results were derived from experiments in an invitro panel of ALK-expressing cell lines.

Direct clinical significance of preclinical data is unproven.

Brigatinib-ALK complex